Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Screening for hydroxychloroquine retinal toxicity: is it necessary?

C D Morsman1, S J Livesey, I M Richards

  • 1Department of Ophthalmology, University Hospital of Wales, Cardiff.

Eye (London, England)
|January 1, 1990
PubMed
Summary

This study found no evidence of retinal toxicity causing vision loss in rheumatoid arthritis patients taking hydroxychloroquine (Plaquenil) for over 18 months. Routine screening for this side effect is no longer necessary in Cardiff.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Anterior chamber angle configuration before and after iridotomy measured by scheimpflug video imaging.

Journal of glaucoma·2009
Same author

IOL material and endophthalmitis.

Eye (London, England)·2008
Same author

FMD and the contiguous cull.

The Veterinary record·2007
Same author

FMD and the contiguous cull.

The Veterinary record·2006
Same author

What factors influence functional ability in patients with rheumatoid arthritis. Do they alter over time?

Rheumatology (Oxford, England)·2005
Same author

Serum soluble interleukin 2 receptor levels and radiological progression in early rheumatoid arthritis.

The Journal of rheumatology·2002

Area of Science:

  • Rheumatology
  • Ophthalmology

Background:

  • Hydroxychloroquine (Plaquenil) is a second-line therapy for rheumatoid arthritis.
  • Long-term use of hydroxychloroquine can potentially cause retinal toxicity.
  • Ophthalmic examinations are typically part of patient monitoring.

Purpose of the Study:

  • To assess retinal toxicity in rheumatoid arthritis patients on long-term hydroxychloroquine therapy.
  • To evaluate the necessity of routine screening for hydroxychloroquine-induced retinal toxicity.

Main Methods:

  • Review of 73 rheumatoid arthritis patients treated with hydroxychloroquine for over 18 months.
  • Analysis of patients receiving monitored dosages and regular ophthalmic examinations.
  • Comprehensive testing for retinal toxicity in patients continuing the medication.

Related Experiment Videos

Main Results:

  • No cases of retinal toxicity causing visual loss were identified in the study cohort.
  • The majority of patients on long-term hydroxychloroquine therapy showed no signs of retinal damage.
  • Recent literature review supports the findings.

Conclusions:

  • Routine screening for hydroxychloroquine retinal toxicity is no longer recommended for rheumatoid arthritis patients in Cardiff.
  • The risk of vision-threatening retinal toxicity appears low in patients on long-term hydroxychloroquine therapy with monitoring.